These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22912565)

  • 21. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
    Guest EJ; Rowland-Yeo K; Rostami-Hodjegan A; Tucker GT; Houston JB; Galetin A
    Br J Clin Pharmacol; 2011 Jan; 71(1):72-87. PubMed ID: 21143503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse drug reactions caused by drug-drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items.
    Kovačević M; Vezmar Kovačević S; Radovanović S; Stevanović P; Miljković B
    Curr Med Res Opin; 2019 Nov; 35(11):1873-1883. PubMed ID: 31328967
    [No Abstract]   [Full Text] [Related]  

  • 23. Mining Directional Drug Interaction Effects on Myopathy Using the FAERS Database.
    Chasioti D; Yao X; Zhang P; Lerner S; Quinney SK; Ning X; Li L; Shen L
    IEEE J Biomed Health Inform; 2019 Sep; 23(5):2156-2163. PubMed ID: 30296244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
    Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2010 Jun; 38(6):981-7. PubMed ID: 20203109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interaction risk with statin switch].
    Molden E; Westergren T
    Tidsskr Nor Laegeforen; 2007 Feb; 127(4):428-31. PubMed ID: 17304269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana.
    Chan JCM; Ng MH; Wong RSM; Tomlinson B
    J Clin Pharm Ther; 2019 Jun; 44(3):381-383. PubMed ID: 30714173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
    Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
    Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.
    Tirkkonen T; Ryynänen A; Vahlberg T; Irjala K; Klaukka T; Huupponen R; Laine K
    Drug Saf; 2008; 31(3):231-40. PubMed ID: 18302447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.
    Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR
    Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites.
    Hu ZY; Parker RB; Laizure SC
    Drug Metab Dispos; 2012 Aug; 40(8):1487-94. PubMed ID: 22563046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drowsiness and motor responses to consecutive daily doses of promethazine and loratadine.
    Baumann-Birkbeck L; Grant GD; Anoopkumar-Dukie S; Kavanagh JJ
    Clin Neurophysiol; 2014 Dec; 125(12):2390-6. PubMed ID: 24791618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians.
    Chan A; Yap KY; Koh D; Low XH; Cheung YT;
    Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):939-47. PubMed ID: 21732473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
    Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.
    Kosugi Y; Hirabayashi H; Igari T; Fujioka Y; Hara Y; Okuda T; Moriwaki T
    Xenobiotica; 2012 Feb; 42(2):127-38. PubMed ID: 22117526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining.
    Morival C; Westerlynck R; Bouzillé G; Cuggia M; Le Corre P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):525-534. PubMed ID: 29255993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.